Đăng xuất
Hypersensitivity to the active substance or to any of the excipients.
Concomitant prolactin-dependent tumours, for example prolactinomas of the pituitary gland and breast cancer.
Phaeochromocytoma.
Combination with levodopa (see Interactions).
Patients with QT interval prolongation (QTc > 440 msg), for example, congenital QT syndrome, or those clinical situations that pose an added risk, such as: Clinically relevant bradycardia (< 50 bpm), History of symptomatic arrhythmia, Any other clinically relevant heart disease, Concomitant treatment with class I or III antiarrhythmic agents, Concomitant treatment with any medicinal product able to prolong the QT interval (see Interactions).
Tiếp tục với Google